Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.

Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates

Prothena Corporation plc (NASDAQ:PRTA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Eric Endicott - Senior Vice President, Corporate Affairs and Communications Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief Medical Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Wagner Zago - Chief Scientific Officer Conference Call Participants Michael Yee - Jefferies Neena Bitritto-Garg - Citi Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Brian Abrahams - RBC Capital Markets Jason Butler - JMP Securities Operator Good afternoon. My name is Audra and I will be your conference operator today.

Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena Corporation plc today reported financial results for the 4th quarter and full year 2022.

Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena Corporation plc announced that it will report its fourth quarter and full year 2022 financial results on February 23, 2023.

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

DUBLIN--( BUSINESS WIRE )--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring a new employee, the compensation committee of the Company's board of directors granted the individual hired by the Company an option to purchase 85,000 ordinary shares of the Company. The option has an exercise price per share equal to $53.67, which was the closing trading price on February 1, 2023, the date of the grant. The option will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grant and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The option was granted pursuant to the Company's 2020 Employment Inducement Incentive Plan, which was approved by the Company's board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN--( BUSINESS WIRE )--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced positive topline Phase 1 single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer's disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms. PRX005 is one of three programs in the global neuroscience research and development collaboration between Prothena and Bristol Myers Squibb.

Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer's Disease

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?

DUBLIN--( BUSINESS WIRE )--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 487,500 of its ordinary shares.

Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

DUBLIN--( BUSINESS WIRE )--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold.

Prothena Announces Proposed Public Offering of Ordinary Shares

DUBLIN--( BUSINESS WIRE )--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis, a statistically significant survival benefit was observed in those treated with birtamimab at 9 months. The survival benefit of birtamimab in VITAL remained consistent across all key baseline variables in patients with Mayo Stage IV AL amyloidosis. The data were presented in an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA.

Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.

Prothena (PRTA) Earns Milestone Payment From Novo Nordisk

DUBLIN--( BUSINESS WIRE )--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $40 million milestone payment from Novo Nordisk related to the continued advancement of NNC6019 (formerly PRX004) in a Phase 2 clinical study for the treatment of ATTR cardiomyopathy. There remains a high unmet medical need in moderate to advanced ATTR amyloidosis patients at high risk for early mortality due to amyloid deposition in vital organs.

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Biogen

Eli Lilly

Roche Holding AG

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others appeared first on Investor's Business Daily.

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others

Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.

Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y

Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2022 and provided a business update.

Prothena Reports Third Quarter 2022 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #ASH22--Prothena Corporation plc today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at ASH 2022.

Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

BioVie Inc

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2022 financial results on Thursday, November 3, 2022 after the close of the U.S. financial markets.

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

Source: Atthapon Raksthaput / Shutterstock.com Prothena (NASDAQ: PRTA ) stock is seeing massive gains on Wednesday despite a lack of news from the late-stage clinical company. However, there is news from Biogen (NASDAQ: BIIB ) that explains why shares of PRTA stock are rising today.

Why Is Prothena (PRTA) Stock Up 75% Today?

Positive results for Biogen's Alzheimer's disease candidate are boosting all three stocks.

Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Prothena (PRTA) Down 16.9% Since Last Earnings Report: Can It Rebound?

DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Helen S. Kim, MBA, to its Board of Directors. Ms. Kim has over 27 years of experience in leadership roles in biotechnology, including her previous role as Executive Vice President of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives, leading to a successful acquisition by Gilead in 2017. With the appointment of Ms. Kim, Prothena will expand its Board to 10 directors.

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

News for Prothena Stock (PRTA)